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1. Introduction 
While acute rejection of solid organ allografts has become a rare clinical condition, long-
term graft survival is threatened by the development of fibrosis. Such fibrosis is seen in two 
forms in the heart, one being an accelerated process of atherosclerosis termed transplant 
vasculopathy, the second a parenchymal response to the ensuing ischemia, low-grade 
cellular or humoral allorejection, as well as other factors.  
The transplant vasculopathy (TV) of cardiac allografts (also known as graft vascular disease, 
chronic allograft vasculopathy or graft vascular sclerosis) is defined as a diffuse proliferative 
process that causes obstruction of the coronary vasculature, impairment of vascular flow 
and secondary myocardial ischemic injury (Mitchell, 2009). Whereas atherosclerosis of non-
transplanted hearts mainly affects the proximal part of the coronary arteries, TV affects the 
arteries down to the level of small intramyocardial branches. Moreover, similar but less 
extensive changes have been observed in coronary veins (Mitchell, 2009), whereas changes 
in capillary basement membrane structure, as seen in chronic kidney rejection biopsies, have 
not been identified as a feature of chronic rejections in hearts.  
The TV lesion consists of concentric intimal thickening that contains modified smooth 
muscle cells that have most likely migrated from the media, macrophages that contain 
intracellular lipids, collagen and glycosoaminoglycans (Winters & Schoen, 2001). 
Cholesterol clefts in a band-like distribution and lesions resembling typical atheromatous 
plaques may arise in the advanced form of the disease. The endothelium and internal elastic 
lamina are nearly always intact. The vascular media may have normal thickness or may be 
thinned. Cellular infiltrates, including T-lymphocytes, both CD4+ and CD8+, and 
macrophages are frequently present as a superficial band in the subendothelium and deeper 
within the intima and media. 
On the other hand, interstitial fibrosis is also a feature of transplanted hearts, partly a 
consequence of the ischemia associated with TV, but also total ischemic time, rejection 
episodes and donor cause of death. Despite these different origins of graft fibrosis, the 
fibrosis lesion (including intimafibrosis in TV) appears to have the occurrence of 
myofibroblasts or myofibroblast-like cells in common. Myofibroblasts are contractile cells 
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thought to partly derive from fibroblasts and to share characteristics with smooth muscle 
cells, including expression of ┙-smooth muscle actin (SMA). They play an important role in 
physiologic wound healing by synthesizing collagens and exerting strong contraction forces 
to minimize wound areas (comprehensive reviews of myofibroblast origins, differentiation 
and functions can be found in (Hinz, 2010; Wipff & Hinz, 2009). Their recruitment is thought 
to be mediated by cellular damage, the release of inflammatory mediators including TLR 
agonists (Wynn, 2008). 
2. Matricellular proteins – between cell and matrix 
The ECM consists of a complex network of structural proteins (collagens, elastin), 
multidomain adhesive glycoproteins (fibronectin, vitronectin, and laminin), 
glycosaminoglycans (GAGs) such as hyaluronan and proteoglycans (versican, syndecans, 
glypicans, perlecan), as well as the matricellular proteins that we shall focus on in this 
chapter. 
Although the main role of ECM is to act as a structural scaffold for tissue and a compression 
buffer when tissues are subjected to stress, its ability to also provide the contextual 
information responsible for controlling cellular behaviour has been increasingly recognized 
in recent years. The biophysical properties of the matrix can regulate cellular 
mechanosensory pathways – through global substrate rigidity or extracellular tension. 
Specific domains and motifs embedded in the ECM proteins act as ligands for cellular 
receptors, such as integrins and discoidin domain tyrosine kinase receptors. In addition, the 
ECM also sequesters and hence acts as a reservoir for a wide range of growth factors and 
cytokines (for reviews see Cox & Erler, 2011; Hynes, 2009; Rhodes & Simons, 2007; Schultz & 
Wysocki, 2009). 
Matricellular protein is a term originally proposed by Bornstein (Bornstein, 1995) to describe 
secreted extracellular matrix proteins that function more as regulators of cell-matrix 
interactions than as structural proteins. The group of matricellular proteins includes 
amongst others thrombospondins, tenascins, osteopontin, periostin, osteonectin or CCN 
proteins. A common property of matricellular proteins is their high expression level during 
embryogenesis, which is strongly reduced after birth and becomes low to absent in adult life 
(although there are organ specific differences). Their expression re-appears at high levels in 
response to tissue injury (Bornstein & Sage, 2002). 
2.1 Osteopontin 
Osteopontin (also known as 44kDa bone phosphoprotein, sialoprotein I, secreted 
phosphoprotein I, uropontin, and early T lymphocyte activation-1) is a multifunctional 
protein thought to play a significant role in a variety of biological processes, including bone 
resorption, immune cell activation, atherosclerosis and ECM remodeling (Scatena et al., 
2007). It belongs to the small integrin binding ligand N-linked glycoprotein (SIBLING) 
family-related proteins. It is composed of 314 amino acid residues and is subject to profound 
posttranslational modifications such as phosphorylation and glycosylation (Waller et al., 
2010). Osteopontin has several molecular domains of established or putative function (see 
Firgure), among them several integrin binding domains: an arginine-glycine-aspartic acid 
(RGD) cell binding sequence interacts with integrins ┙v┚3, ┙v┚1, ┙v┚5 and ┙8┚1, a serine- 
www.intechopen.com
 
Role of Matricellular Proteins in Cardiac Allograft Fibrosis 
 
101 
 
Fig. 1. Structural models of matricellular proteins. 
Osteopontin: MBD = matrix binding domain, the integrin binding specificity is indicated below 
corresponding domains; Thrombospondins: NTD = N-terminal domain, vWC = von Willebrand factor type 
C domain, TSP = thrombospondin, red box indicates conserved domains, Tenascins: in red = N-terminal 
oligomerisation domain, FN = fibronectin; Osteonectin with the three characteristic domains of SPARC-like 
proteins; Periostin: FAS1 domain = fasciclin-like domain 1; CCN proteins:; IGFBP = insulin-like growth 
factor binding protein homology domain, CT = C-terminal domain, HSPG = heparan sulfate proteoglycan, 
integrin and HSPG binding sites are indicated in colored bars, dashed line indicates the hinge region 
(adapted from publications Adams & Lawler, 2004; Brekken & Sage, 2000; C. C. Chen & Lau, 2009; 
Chiquet-Ehrismann & Chiquet, 2003; Conway & Molkentin, 2008; Lund et al., 2009; Scatena et al., 2007).  
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valine-valine-tyrosine- glutamate-leucine-arginine (SVVYGLR)-containing domain that 
interacts with integrins ┙9┚1, ┙4┚1 and ┙4┚7 and a ELVTDFPTDLPAT domain is also 
reported to bind to ┙4┚1 (Waller et al., 2010). Several cell types have the capacity to 
synthesize osteopontin, including bone cells, macrophages, endothelial cells, smooth muscle 
cells and fibroblasts (Schellings et al., 2004). In healthy adult organs osteopontin expression 
is low except for the kidney, bone, and in epithelial linings of several tissues (Schellings et 
al., 2004). By contrast, osteopontin expression is upregulated in pathological conditions, 
such as atherosclerosis (Giachelli et al., 1993) and ischemic injury (Ellison et al., 1998) 
including myocardial infarction (MI) (Tamura et al., 2003).  
2.2 Thrombospondins  
The known vertebrate thrombospondins fall into two subgroups, termed A (thrombospondin-
1 and -2) and B (thrombospondin-3, -5, and -5/COMP) according to their oligomerization 
status. Hence, members of subgroup A form homotrimers and members of subgroup B 
homopentamers. Each thrombospondin contains multiple domains and a coiled-coil 
oligomerisation region (Figure). The hallmark of all thrombospondins is the presence in the 
carboxy-terminal half of each polypeptide of a variable number of EGF-like domains that are 
contiguous with seven so-called thrombospondin type 3 repeats and a C-terminal region of 
globular character (Adams & Lawler, 2004). 
The most well described members of the family are thrombospondin-1 and -2. Important 
functions of thrombospondin-1 are activation of the TGF- (transforming growth factor-┚, 
see below), inhibition of angiogenesis and de-adhesion of cells. The anti-angiogenic effect of 
thrombospondin-1 is caused mostly by induction of apoptosis and inhibition of endothelial 
cell migration (Nor et al., 2000). Thrombospondin-1 also induces de-adhesion , defined as 
transition to an earlier stage of adhesion process (Greenwood & Murphy-Ullrich, 1998), in a 
variety of cells, by stimulating loss of focal adhesions and actin stress fibers (Greenwood & 
Murphy-Ullrich, 1998; Murphy-Ullrich & Hook, 1989). Likewise, thrombospondin-2 has 
been shown also to inhibit angiogenesis and cause de-adhesion by inhibiting focal adhesion 
in endothelial cells (Murphy-Ullrich et al., 1993, for review see Schellings et al., 2004). 
2.3 Tenascins  
The tenascin family includes: tenascin-C, -R, -X, -Y and -W. They are all built from a 
common set of structural motifs: heptad repeats, EGF-like repeats, fibronectin type III 
repeats and a fibrinogen globe domain (FBG, see Figure). At the N-terminus each tenascin 
has an oligomerisation domain that in the case of tenascin-C and -W leads to the formation 
of hexamers while tenascin-R has been isolated as a trimeric molecule (Racanelli et al., 1992).  
Tenascin-C expression is very low after birth and in the normal adult heart its expression is 
limited to the chorda tendinae of papillary muscles (Sato & Shimada, 2001). However, the 
protein reappears under pathological conditions, such as infection, vascular hypertension, 
myocardial infarction and experimental autoimmune myocarditis (Imanaka-Yoshida et al., 
2001; Imanaka-Yoshida et al., 2002). Tenascin-C has adhesive and de-adhesive properties, 
depending on ECM composition and cell surface receptor binding. De-adhesion facilitates 
cell migration and tissue remodeling during wound healing. In contrast to tenascin-C, 
tenascin-X expression remains high after birth (Geffrotin et al., 1995) and has been shown to 
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mediate cell adhesion but not spreading (Elefteriou et al., 1999) Moreover, tenascin-X 
modulates collagen fibrillogenesis and is therefore described in more detail below. 
2.4 Osteonectin/SPARC 
Osteonectin (also known as SPARC (Secreted Protein Acidic and Rich in Cysteine) or BM-
40) is a 32-kDa glycoprotein characterized by three modular domains (Figure): (1) an N-
terminal acidic and low-affinity calcium-binding domain; (2) a disulfide-bonded, copper-
binding follistatin domain (homologous to the TGF┚-inhibitors activin and inhibin), and (3) 
the C-terminal extracellular calcium-binding domain (Clark et al., 1997; Schellings et al., 
2004). 
Tissue expression of osteonectin in healthy adult organs is very low except in epithelia that 
exhibit high turnover rates (gut, skin, and glandular tissue) (Sage et al., 1989). However, like 
the preceding matricellular proteins, osteonectin expression re-appears in lesions of injury 
such as myocardial infarction (Komatsubara et al., 2003). Osteonectin has been reported to 
bind to thrombospondin-1, vitronectin, entactin, fibrillar collagens and collagen type IV 
(Schellings et al., 2004). Additionally, it inhibits endothelial cell adhesion and proliferation 
(Rosenblatt et al., 1997). The de-adhesive effect is mediated through a tyrosine 
phosphorylation-dependent pathway, whereas its antiproliferative function is dependent, in 
part, on signal transduction via a G protein-coupled receptor (Motamed & Sage, 1998). 
Absence of osteonectin in mice during embryogenesis resulted in pups with curly tails and 
reduced tensile strength of the skin. Smaller collagen fibrils that were more uniform in 
diameter were seen at the ultrastructural level (Schellings et al., 2004).  
2.5 Periostin 
Periostin (osteoblast specific factor-2, OSF-2) (reviewed in refs. Conway & Molkentin, 2008; 
Norris et al., 2009) has a molecular weight of ~90 kDa and consists of), four-coiled fasciclin-
like repeats, an aminoterminal cysteine-rich region (EMI domain), and heparin binding 
domains present in the carboxyl tail (Figure). In the heart, periostin is expressed at the very 
early stages of embryogenesis; however, it is not detected in the normal adult myocardium, 
except in the valves (Kruzynska-Frejtag et al., 2001; Norris et al., 2007).  
Periostin can directly interact with other ECM proteins such as fibronectin, tenascin-C, 
collagen I, collagen V, and heparin and serve as a ligand for integrins ┙v┚3, ┙v┚5 and ┙4┚6. 
Recently, it was demonstrated that periostin plays a crucial role in activation of fibroblasts 
and smooth muscle cells (SMC) through FAK-integrin signaling (Li et al., 2010; Shimazaki et 
al., 2008). It also promotes collagen fibril formation (Maruhashi et al., 2010; Norris et al., 
2007) and incorporation of tenascin-C, organizing a meshwork architecture of the ECM (Kii 
et al., 2010). 
2.6 CCN protein family 
CCN (an acronym formed from names of first three members) proteins family (reviewed in 
Chen & Lau, 2009; Kular et al., 2011) includes 6 members: CYR61 (cysteine-rich 61; CCN1), 
CTGF (connective tissue growth factor; CCN2), NOV (nephroblastoma over-expressed; 
CCN3), CCN4 (WISP1), CCN5 (WISP2), and CCN6 (WISP3). All members share a 
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multimodular structure, with an N-terminal secretory signal sequence followed by four 
conserved domains with homology to insulin-like growth factor binding proteins (IGFBPs), 
von Willebrand factor type C repeat (VWC), thrombospondin type I repeat (TSP) and a 
carboxyterminal domain (CT) containing a cystein knot (with the exception of CCN5, see 
figure). A multimodular structure of the CCN proteins allows them to bind and interact 
with a broad range of partners including integrins, heparan sulfate proteoglycans (HSPGs), 
ECM components such as fibronectin and fibulin 1C, receptors like Notch1, TrkA, low-
density lipoprotein receptor-related proteins (LRPs), growth factors including BMPs, TGF-┚ 
and VEGF, as well as gap junction protein connexin 43. CCN proteins regulate cellular 
functions such as adhesion, migration, proliferation, differentiation, survival, apoptosis or 
extracellular matrix remodelling in a cell-type specific manner and they play crucial roles in 
vascular and skeletal development, angiogenesis, wound healing, fibrosis, vascular disease 
or cancer. 
3. Matricellular proteins in action 
3.1 Matricellular proteins in solid organ transplantation  
Data on matricellular protein expression and function in the cardiac allografts is limited 
(Franz et al., 2010; Mikalsen et al., 2010; Zhao et al., 2001) but justifies further investigation. 
For example, TV has been associated with elevated levels of thrombospondin-1 (Zhao et al., 
2001) and of tenascin-C (Franz et al., 2010). Moreover, the tenet of endothelial cell activation 
being at the epicentre of TV pathogenesis leads to the logic that we need a focussed 
understanding of how this cell type responds without the confounding noise generated 
from other cell types. Initial studies in our lab were therefore founded on the purification of 
endothelial cells from heterotopic cardiac grafts in the rat during rejection (Mikalsen et al., 
2010). Grafts were fully mismatched (DA to Lewis), leading to a full rejection and loss of 
graft function at day 5-6, and were compared to isografts (Lewis to Lewis) to discriminate 
allogenicity from the surgical procedure. The extent of this analysis is a transcriptome-wide, 
Affymetrix-based profile of rejection on day 2, 3 and 4 and a corresponding profile of the 
isograft. Among the most interesting features of these profiles was, first, the observation that 
tenascin-C and periostin were the most strongly induced transcripts and, second, that the 
majority of transcriptional changes were similar between the allo- and isografts. These data 
are publicly available at the NCBI GeneExpression Omnibus (GSE16695).  
Another observation of relevance is that cyclosporine and tacrolimus have been shown to 
induce osteopontin mRNA expression in renal tissues in vitro and in vivo (Khanna, 2005). 
Cyclosporine has been reported to induce upregulation of osteopontin by tubular epithelial 
cells resulting in macrophage infiltration and fibrosis in a rat model of chronic cyclosporine 
nephropathy. Whether these findings have an impact on cardiac allografts is uncertain. It 
appears that cyclosporine does not promote clinical TV (Gamba, Mammana, Fiocchi, Iamele, 
& Mamprin, 2000; Rickenbacher et al., 1996), despite a large amount of experimental data 
suggesting a profibrotic effect, including enhanced production of TGF-┚. 
In addition, Sawada and coworkers studied the role of tenascin-C during abdominal aorta-
to-carotid artery interposition grafting in mice (Fischer, 2007; Sawada et al., 2007). When 
aortas derived from tenasin-C-deficient mice were grafted to carotid arteries of tenascin-C-
deficient recipients, neointimal hyperplasia and VSMC proliferation was significantly 
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reduced compared with WT-to-WT grafting. Furthermore, even if only the graft or the 
recipient was tenascin-C-deficient, dramatic reductions of neointimal hyperplasia occurred. 
3.2 Matricellular proteins in ischemic injury 
Given that data on matricellular protein expression and function in cardiac allograft fibrosis 
is currently very limited, it is interesting to look at the role of these proteins in cardiac 
healing and remodeling after experimental MI. Interestingly, lack of several matricellular 
proteins reveals remarkable phenotypes in this context (for review see Matsui et al., 2010), 
most of them (with the exception of thrombospondin-1) showing signs of reduced repair 
and resulting ventricular dilation.  
Thus, osteopontin-deficient mice show significantly stronger ventricular dilation, reduced 
collagen synthesis and deposition in both infarcted and non-infarcted regions compared to 
wild-type (WT) mice (Trueblood et al., 2001). Moreover, expression and activity of MMP-2 
and MMP-9 is significantly higher in the non-infarct LV in mice lacking osteopontin 3 days 
post-MI. The increased MMP-2 activity in the KO group persisted over the next 14 days 
suggesting that osteopontin modulates MMP expression and activity in the heart post-MI, 
thereby playing an important role in regulation of collagen deposition and fibrosis. While 
MMP inhibition improved heart function in both WT and KO mice, this improvement was 
significantly higher in mice lacking osteopontin (Krishnamurthy et al., 2009). Thus, it 
appears that increased osteopontin expression protects the heart from ventricular dilation 
and is required to maintain the structure and function of the heart after ischemic injury.  
Moreover, thrombospondin-1-deficient mice exhibit severe inflammation and expansion of 
the ischemic lesion, as well as enhanced ventricular dilatation (Frangogiannis et al., 2005), 
whereas thrombospondin-2-deficient mice developed cardiac failure in response to 
angiotensin II infusion, followed by fatal cardiac rupture in 70% of the cohort. Wild-type 
controls showed no signs of cardiac failure (Schroen et al., 2004). 
Likewise, a targeted inactivation of osteonectin exhibited an increased incidence of cardiac 
rupture and failure after MI, resulting in a fourfold increase in mortality. Ostonectin-null 
infarcts had a disorganized granulation tissue and immature collagenous ECM. In contrast, 
adenoviral overexpression of osteonectin in WT mice improved the collagen maturation and 
prevented cardiac dilatation and dysfunction (Schellings et al., 2009). 
In a similar manner, periostin-deficient mice have an increased incidence of cardiac rupture 
following experimental MI, associated with decreased recruitment of myofibroblasts and 
impaired collagen fiber formation in the lesion. However, surviving periostin-deficient mice 
have less fibrosis and significantly better cardiac performance (Matsui et al., 2010; Oka et al., 
2007; Shimazaki et al., 2008).  
By contrast, the effect of tenascin-C depletion on cardiac healing and remodeling after 
experimental MI was that end-diastolic pressure, ventricle dimension and myocardial 
stiffness were less increased of KO+MI compared to WT+MI mice (Nishioka et al., 2010). 
Histological examination revealed normal tissue healing, but interstitial fibrosis in the 
residual myocardium of the peri-infarcted areas was significantly less pronounced in 
KO+MI mice than in WT+MI mice (Nishioka et al., 2010), perhaps due to the delayed 
appearance of myofibroblast in tenascin-C-deficient mice (Tamaoki et al., 2005). 
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3.3 Effect of matricellular proteins in the inflammatory response  
Given that atherosclerosis, TV, cellular and humoral rejection as all chronic inflammatory 
conditions, it deserves focus to also discuss the role of matricellular proteins in this context. 
3.3.1 Osteopontin 
Osteopontin affects inflammatory responses at many different levels (reviewed in Lund et 
al., 2009 and Scatena et al., 2007). First, osteopontin plays a crucial key role in macrophage 
biology by regulating migration, survival, phagocytosis, and pro-inflammatory cytokine 
production in vitro (Lund et al., 2009; Weber et al., 2002). Conversely, osteopontin is induced 
by several inflammatory cytokines in macrophages, including TNF-┙, IL-1┚, IFN-┛, and IL-6, 
and other factors such as angiotensin-II, oxidizedLDL, and phorbol-ester (Lund et al., 2009). 
In CD4+ and CD8+ lymphocytes, osteopontin is strongly induced in response to T cell 
receptor ligation (Shinohara et al., 2005). In vivo, subcutaneous injection of ostopontin leads 
to recruitment of macrophages (Giachelli et al., 1998) and in osteopontin-deficient mice, 
macrophage infiltration is greatly diminished compared to wild-type mice in both acute and 
chronic inflammation models such as unilateral uretheral obstruction (UUO) model 
(Ophascharoensuk et al., 1999) or type II collagen antibody-induced arthritis (Yumoto et al., 
2002). Osteopontin has also been also reported to regulate T cells migration, adhesion, co-
stimulation and proliferation (O'Regan et al., 1999; Patarca et al., 1993) as well as migration 
of neutrophils (Koh et al., 2007) and dendritic cells (Weiss et al., 2001). Moreover, 
osteopontin can modulate the immune response by enhancing expression of Th1 cytokines 
by promoting expression of IL-12 and inhibiting that of IL-10 (Ashkar et al., 2000). In 
addition, there is evidence that matrix degrading enzymes are affected, as matrix 
metalloprotease (MMP)-2 and MMP-9 activity was reduced after angiotensin II infusion in 
osteopontin KO mice (Bruemmer et al., 2003) and macrophages stimulated with osteopontin 
in vitro upregulated activated MMP-9 (Weber et al., 2002). 
3.3.2 Tenascin C 
Midwood and coworkers reported recently that tenascin-C, acting as an endogenous 
activator of TLR4-mediated immunity, mediates persistent synovial inflammation and tissue 
destruction in arthritic joint disease (Midwood et al., 2009). In vitro, TLR4 ligation also 
stimulated synthesis of TNF-┙, IL-6 and IL-8 in primary human macrophages and IL-6 in 
synovial fibroblasts. TLR4-binding has been mapped to the FBG domain of tenascin-C at the 
carboxy terminus of the molecule. Interestingly, tenascin-C does not seem to be involved in 
the initiation of inflammation but it is required for the maintenance of joint inflammation, 
perhaps reflecting that it is absent from healthy tissue and needs induction by inflammatory 
mediators (Goh et al., 2010). The key role of tenascin-C in prolonging joint inflammation was 
underscored by the protection of tenasin C-/- mice from sustained and erosive joint 
inflammation (Midwood et al., 2009). Tenascin C can also stimulate cytokine synthesis in 
murine synovial fibroblasts via activation of ┙9 integrins (Kanayama et al., 2009).  
Moreover, tenascin-C appears to be involved in regulation of lymphocyte migration as it 
supports adhesion and rolling of primary human peripheral blood and tonsillar 
lymphocytes (Clark et al., 1997). In addition, tenascin-C KO mice exhibit reduced 
lymphocyte infiltration and lower levels of IFN, TNF and IL-4 mRNA upon concanavalin A-
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induced liver injury (El-Karef et al., 2007). Furthermore, tenascin-C may be involved in 
lymphocyte activation although both stimulatory and inhibitory effects have been reported. 
Tenascin-C significantly stimulates the secretion of IL-5, IL-13, IFN-g and immunoglobulin-
E from spleen lymphocytes (Nakahara et al., 2006). However, it has inhibitory effect on the 
anti CD3-induced activation of human peripheral blood T cells irrespectively of 
costimulatory molecules used (Hemesath et al., 1994; Hibino et al, 1998) and it was also 
found to inhibit T cell activation induced by alloantigens (Ruegg et al., 1989).  
Conversely, Tenascin-C synthesis is a target of inflammatory stimuli: it is specifically 
induced in immune myeloid cells by ligands to TLRs located at the cell surface (TLR2, 4, and 
5), but not by those targeting TLRs in the endosome; (TLR3 or TLR8) (Goh et al., 2010). 
Tenascin-C expression is rapidly and transiently induced in immune myeloid cells in 
response to tissue injury and infection (Midwood & Orend, 2009). It therefore appears that 
induction of tenascin-C in an inflammatory setting would drive TLR4 activation leading to 
synthesis of more tenascin-C, perhaps resulting in a nonresolving loop of chronic 
inflammation (Goh et al., 2010).  
3.4 Matricellular protein’s role in the TGF-β signaling pathway 
TGF-┚ is pivotal in TV and in fibrosis in general. Several matricellular proteins are involved 
in promoting TGF signalling. They are either involved in promoting synthesis of TGF 
(osteonectin, periostin), activating of the cytokine itself (thrombospondin-1 and possibly 
periostin) or enhancing the signalling of its receptor (osteonectin). In addition, some 
matricellular proteins are downstream targets of TGF signalling (CCN2). To enhance 
understanding of the different modes of action it is necessary to explain the complex 
pathway of TGF activation: Precursors of the TGF-┚ isoforms 1 to 3 are cleaved by a furin 
protease to generate mature TGF-┚ and its propeptide, also known as latency-associated 
peptide (LAP). LAP and mature TGF-┚ remain noncovalently associated in a complex called 
the small latency complex (SLC), and in this form, TGF-┚ remains inactive. The LAPs then 
binds to one of the latent TGF-┚–binding proteins (LTBPs) to form large latent complexes 
(LLCs). The LTBPs bind to ECM proteins including fibrillins and fibronectin, thereby 
incorporating the different latent TGF-┚ isoforms into extracellular matrices. There are 
several mechanisms for activation, one of them involving thrombospondin-1 binding and 
LAP dissociation (Hynes, 2009).  
Thrombospondin-1-induced activation of TGF-┚ was reported for first time in 1992 by 
Murphy-Ullrich and coworkers (Murphy-Ullrich et al., 1992) and since then 
thrombospondin-1 domains responsible for TGF binding have been identified (reviewed H. 
Chen, Herndon, & Lawler, 2000). The significance of this process confirmed both in vitro 
and in vivo, including angiotensin II–induced upregulation of thrombospondin leading to 
TGF-┚ activation by cardiac and renal cells (Zhou et al., 2006) as well as a role for 
thrombospondin-1 in mesangial proliferative glomerulonephritis (Daniel et al., 2004) and 
diabetic nephropathy (Daniel et al., 2007). 
Osteonectin/SPARC acts at two levels: first, it is involved in stimulating TGF production 
(Schiemann et al., 2003) and second, osteonectin modulates the TGF-┚1-dependent 
phosphorylation of Smad-2 in primary mesangial cells through an interaction with the TGF-
┚1-receptor complex, but only in the presence of TGF-┚1 bound to its cognate type II 
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receptor (Francki et al., 2004). Osteonectin mediated modulation TGF-┚ signaling has been 
also shown in cardiac fibroblasts in vitro. Most importantly, infusion of TGF-┚ can rescue 
the cardiac rupture phenotype in osteonectin-null mice (Schellings et al., 2009).  
In a recently published study Sidhu and coworkers demonstrated increased TGF-┚ 
production and enhanced TGF-┚ bioactivity both in periostin-overexpressing epithelial cells 
and in primary airway epithelial cells stimulated with recombinant periostin and suggested 
that periostin is an upstream regulator of TGF-┚ activation in a mechanism involving MMP2 
and -9 (Sidhu et al., 2010). On the other hand, CCN2/CTGF acts as a downstream mediator 
of TGF-┚-induced fibroblasts proliferation, myofibroblast differentiation (Grotendorst et al., 
2004; Kothapalli et al., 1997) and collagen synthesis (Duncan et al., 1999). CTGF synthesis is 
induced by TGF-┚ in fibroblasts via a unique TGF-┚ response element in the CTGF 
promoter, and blockade of CTGF synthesis or action effectively inhibits these TGF-┚ effects 
on fibroblasts. Further research has revealed that the two domains of CTGF function 
mediate two distinct biological effects, the N-terminal domain myofibroblast differentiation 
and collagen synthesis and the C-terminal domain fibroblast proliferation (Grotendorst & 
Duncan, 2005). Interestingly, another member of CCN family – CCN3 (Nov) may act as an 
endogenous negative regulator of CCN2 with the capacity to limit the overproduction of 
extracellular matrix (ECM), and thus prevent or ameliorate fibrosis (Riser et al., 2010). Over-
expression of the CCN3 gene in mesangial cells markedly down-regulates CCN2 activity 
and blocks ECM over-accumulation stimulated by TGF-┚1. Conversely, TGF-┚1 treatment 
reduces endogenous CCN3 expression and increases CCN2 activity and matrix accumulation 
(Riser et al., 2010). Additionally, when cultured mesangial cells are exposed to exogenous 
CCN3 protein, TGF-┚ stimulated increase in CCN2 is attenuated in a dose-dependent manner 
(Riser et al., 2009). 
Osteopontin, similar to CCN2, also mediates the TGF-┚ signaling involved in the 
differentiation of fibroblasts into myofibroblasts. This conclusion is based on the observation 
that ┙-smooth muscle actin is not expressed in TGF-┚–treated cardiac fibroblasts isolated 
from osteopontin-null mice and additionally confirmed by small interfering RNA 
knockdown of osteopontin in fibroblasts from wild-type mice (Lenga et al., 2008). 
3.5 Matricellular proteins in myofibroblast differentiation and SMC recruitment 
TGF-┚ is thought to provide a crucial signal that initiates differentiation of myofibroblasts 
(Leask, 2010), partly acting by altering focal adhesion kinase activatity, up-regulating 
expression of integrin receptors and induction of the fibronectin splice variant ectodomain 
(ED)-A (Ffrench-Constant et al., 1989; Serini et al., 1998). While matricelular proteins can 
influence myofibroblast differentiation via modulation of TGF-┚ signalling as described in 
previous section, there is growing evidence that matricellular proteins can influence 
fibroblast recruitment and differentiation also by other mechanisms. 
3.5.1 Tenascin C  
Tamaoki and coworkers, studying tissue repair after myocardial injury observed that the 
appearance of myofibroblasts was delayed in tenascin-C KO mice, although myocardial 
repair appeared to proceed normally. Moreover, cardiac fibroblasts from tenascin-C KO 
mice showed lower cell migration and ┙-SMA expression than WT cells that synthesize 
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tenascin-C in culture. Addition of tenascin-C to tenascin-C-null cells recovered both cell 
migration and ┙-SMA expression. Functional domains of tenascin-C protein responsible for 
inducing myofibroblast differentiation were mapped to alternatively spliced FNIII repeats 
(but not the conserved repeats) and the FGB domain. In contrast, the molecular signal that 
promoted migration of cardiac fibroblasts was mapped to the domain of conserved FNIII 
repeats and the FGB domain (Tamaoki et al., 2005). 
3.5.2 Periostin 
Recently, Shimazaki and coworkers reported that impaired cardiac healing after an acute 
myocardial infarction in periostin-KO mice was associated with reduced numbers of alpha 
smooth muscle actin-positive cells. The authors suggested a model in which periostin signals 
via ┙v-integrin, FAK, and Akt, activates cell migration of cardiac fibroblasts from outside into 
the infarct region, and then supports their differentiation into ┙SMA-positive fibroblasts, 
resulting in enhanced stiffness of the LV wall through collagen synthesis after AMI (Shimazaki 
et al., 2008). Interestingly, periostin has been shown also to mediate vascular smooth muscle 
cell migration through mechanisms similar to those described above engaging the integrins 
┙v┚3 and ┙v┚5 and focal adhesion kinase (FAK) pathway (Li et al., 2010).  
3.6 Matricellular proteins in ECM assembly and collagen fibrillogenesis  
An identification of the factors that control collagen fibril formation and ECM assembly is 
critical for an understanding of tissue organization and the mechanisms that lead to fibrosis. 
There is growing evidence that matricellular proteins may play an important role in these 
processes not only via effects on TGF-┚ signaling pathway. Below we have listed a few 
examples suggesting potential mechanisms of matricellular proteins involvement in 
collagen synthesis and maturation.  
3.6.1 Tenascin X – effect on matrix mechanical properties 
A crucial role in tenascin-X collagen biology is suggested by the fact that its deficiency is 
associated with the Ehlers-Danlos Syndrome in humans (Burch et al., 1997). Major clinical 
symptoms consist of skin hyperextensibility and joint laxity, while ultrastructural analyses 
reveal abnormalities in collagen fibril networks and elastic fibre morphology. Mice deficient 
in tenascin-X partly reproduced this phenotype (Mao et al., 2002). In vitro studies revealed 
that tenascin-X interacts with fibrillar collagen type I, III and V when they are in native 
conformation. Additional studies indicated that both epidermal growth factor repeats and 
the fibrinogen-like domain are involved in this interaction (Lethias et al., 2006) and although 
the presence of tenascin-X does not significantly influence the main parameters of 
fibrillogenesis and diameter of fibrils, mechanical analysis of collagen gels showed an 
increased compressive resistance of the gels containing tenascin-X, indicating that this 
protein might be directly involved in determining the mechanical properties of collagen-rich 
tissues in vivo (Margaron et al., 2010). 
3.6.2 Osteonectin – effect on procollagen I processing 
Adult osteonectin-null mice exhibit decreased amounts of collagen in skin (Bradshaw et al., 
2003). In addition, fibrotic deposition of collagen in mice with bleomycin-induced 
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pulmonary fibrosis is diminished in the absence of osteonectin (Strandjord et al., 1999), 
Moreover, Rentz and coworkers investigated collagen I production in osteonectin-null 
dermal fibroblasts observing that osteonectin might be involved in regulation of procollagen 
I processing (Rentz et al., 2007). The ┙1(I) and ┙2(I) subunits of procollagen I are synthesized 
with N- and C-propeptides that are enzymatically released by specific proteases. Processing 
of procollagen I to collagen I is essential for correct assembly of collagen fibrils and 
regulation of procollagen processing has been proposed as a potential regulatory event in 
collagen fibril assembly (Prockop & Kivirikko, 1995). Although osteonectin-null dermal 
fibroblasts exhibited an increased association of collagen I with cell layers and enhanced 
processing of procollagen1(I) to collagen1(I). The processed collagen I was not efficiently 
incorporated into osteonectin-null detergent-insoluble cell layers, and collagen fibers that 
formed on osteonectin-null cells did not persist to the same extent as those on WT cells 
(Rentz et al., 2007).  
3.6.3 Periostin – an effect on collagen I cross-linking  
Collagen fibrils from periostin-deficient mice show reduced size, organisation, and less 
efficient cross-linking (Norris et al., 2007; Shimazaki et al., 2008). Recently, Maruhashi and 
coworkers (Maruhashi et al., 2010) proposed a model to explain periostin’s role in 
determining ECM integrity. Collagen fibrils are stabilized by the formation of intra- and 
intermolecular cross-linking that is catalyzed by the enzyme lysyl oxidase (LOX). The 
activity of LOX is regulated by proteolytic cleavage of its inactive precursor, pro-LOX, by 
BMP-1 (bone morphogenetic protein-1; also known as pro-collagen C-proteinase) (Uzel et 
al., 2001). Periostin binds to BMP-1 and promotes the proteolytic activation of pro-LOX. As 
it has been shown that periostin also interacts with fibronectin (Takayama et al., 2006), the 
model suggest periostin-mediated scaffolding for the interaction between pro-LOX and 
BMP-1 on the fibronectin matrix (Maruhashi et al., 2010). 
4. Matricellular proteins in therapy 
Although modulation of matricellular protein function has not yet been subject to clinical 
trials, there is growing evidence from experiments in animal models that this approach can 
be beneficial in many diseases including fibrosis. Here, we present a few of models of 
experimental therapy involving matricellular proteins. 
4.1 Depletion of microcellular protein by antisense or siRNA 
Adenovirus-mediated inhibition of osteonectin markedly attenuated the development of 
hepatic fibrosis in rats treated with thioacetamide, as assessed by decreased collagen 
deposition, lower hepatic content of hydroxyproline and less advanced morphometric stage 
of fibrosis. Osteonectin depletion also reduced inflammatory activity and suppressed 
transdifferentiation of hepatic stellate cell to the myofibroblasts-like phenotype (Camino et 
al., 2008). In another approach, osteonectin siRNA treatment through subcutaneous injection 
or intratracheal instillation was found to markedly reduce fibrotic changes in skin and lungs 
in murine models of skin and lung fibrosis induced by bleomycin (Wang et al., 2010).  
Morover, antisense oligonucleotides against thrombospondin-1 were used to inhibit 
activation of TGF-┚ in a rat model of mesangial proliferative glomerulonephritis, in which 
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TGF-┚ has been demonstrated to mediate renal fibrosis. The antisense-mediated reduction 
of thrombospondin did not reduce the expression of TGF-┚ but rather inhibited the TGF-┚-
dependent smad-signalling pathway, as well as the transcription of TGF-beta target genes, 
resulting in a markedly suppressed accumulation of extracellular matrix (Daniel et al., 2003). 
4.2 Modification of matricellular protein function by antagonist  
In a rat model of type 1 diabetes in which diabetic cardiomyopathy is exacerbated by 
abdominal aortic coarctation, Belmadani and coworkers observed that a peptide antagonist 
of thrombospondin-1-dependent TGF-┚ activation prevented progression of cardiac fibrosis 
and improved cardiac function (Belmadani et al., 2007). In an analogous experiment, 
treatment with a peptide antagonist of thrombospondin-1 attenuated renal interstitial 
fibrosis in rats with unilateral ureteral obstruction (Xie et al., 2010). 
4.3 Overexpression of matricellular protein  
Thrombospondin-2 overexpression via thigh muscle transfection was studied in the anti-Thy1 
glomerulonephritis model. Muscular overexpression of thrombospondin-2 reduced 
glomerular TGF-┚ activation and glomerular extracellular matrix formation as determined by 
collagen IV and fibronectin. In addition, activation of mesangial cells to the myofibroblast-like 
phenotype was also significantly decreased in thrombospondin-2-overexpressing animals 
(Daniel, Wagner, Hohenstein, & Hugo, 2009). Additionally, thrombospondin 1 overexpression 
was suggested as a gene therapeutic strategy in collagen-induced arthritis (CIA). Direct 
intraarticular administration of adenoviral vectors encoding thrombospondin-1 significantly 
ameliorated the clinical course of CIA in rat model (Jou et al., 2005).  
5. Models of fibrosis 
Animal models of chronic allograft injury have been comprehensively described in a recent 
review (Bedi et al., 2010). 
5.1 Heterotopic cardiac transplantation  
The model of heterotopic cardiac transplantation is and has been widely used to study 
chronic allograft injury and rejection. It also provides information relevant to graft ischemia-
reperfusion injury, allorejection and immunosuppressants, as well as physiologic changes 
that take place post-transplant in vascularized organs. In comparison to orthotopic 
transplantation, the heterotopic procedure is technically less demanding and does not 
require a cardiopulmonary bypass. After pioneer transplantation experiments in large 
animals, Abbott et al. described a method of vascularised abdominal heterotopic heart 
transplantation in rats in 1964 (Abbott et al., 1964). Ono and Lindsay improved the 
technique by end-to-side anastomosis of the donor vessels to the recipient’s aorta and IVC, 
resulting in a higher recipient survival rate (Ono & Lindsey, 1969). This method has been 
widely used, adopted to use in mice and improved by several modifications (Hasegawa et 
al., 2007; Shan et al., 2010).  
Of particular relevance to TV, Adams et al. described cardiac allografting across minor 
histocompatibility barriers (Lewis-F344 model) (Adams et al., 1993). Advantages of the 
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Lewis-F344 model are commercial availability and easily recognizable inflammatory stages 
of lesion development. On the other hand, grafts have relatively low long-term survival 
rates (25%) and they show substantially more severe mononuclear infiltration and necrosis 
when compared to human TV lesions (Adams et al., 1993), unless they were exposed to high 
levels of cyclosporin, in which case TV failed to develop (Poston et al., 1999). Although the 
Lewis-F344 model remains commonly used, Poston et al. argued that a model in which TV 
developed despite immunosuppression, would more appropriately reflect a situation where 
cell mediated alloimmunity is not the sole or major pathogenesis (Poston et al., 1999). This 
situation is seen in the PVG (Piebald Viral Glaxo, RT1c)-to-ACI (August Copenhagen Irish, 
RT1a) which is a fully-mismatched MHC class II model. However, a disadvantage of the 
PVG-to-ACI model is that it fails to induce myocardial rejection. Nevertheless, in this model, 
rapamycin, but not cyclosporin, is capable of reducing the degree of chronic graft vascular 
disease and opens the door for investigators to study chronic injury in a model that is 
relatively resistant to T-cell– directed immunosuppressants (like cyclosporin) but 
susceptible to novel agents whose mechanism of actions lies beyond reduction in T-cell–
mediated immunity. 
Murine models of chronic allograft injury include those involving different strains with 
minor histoincompatibilities, which usually leads to a smoldering immunologic response 
within the allograft and ultimately, chronic injury (Bedi et al., 2010).  
An established mouse model of TV is an MHC class II-mismatched heterotopic graft from 
B6.C.H-2-bm12 (bm12) into a wild-type C57BL/6 (B6, H-2b) mouse. Bm12 mice are a variant 
strain of C57BL/6 mice, in which a spontaneous mutation has occurred in the I-Ab locus, 
designated I-Abm12. In this single MHC class II mismatch model, the majority of bm12 
cardiac allografts survive up to 100 days and develop significant vasculopathy, notable for 
intraluminal accumulation of mononuclear leukocytes (at 4 weeks posttransplant), intimal 
lesions (by 8 weeks), and accumulation of smooth muscle cells signifying fibroproliferative 
arteriosclerotic lesions (by 12 weeks; Fig. 2). The limited alloreactive T-cell activation and 
emergence of a population of regulatory T cells allow long-term allograft survival with the 
development of significant vasculopathy (Bedi et al., 2010). 
As in rat models, heterotopic cardiac transplantation between fully MHC-mismatched 
mouse strains has been described as models for studying chronic rejection with the use of 
postoperative immunosuppressants to prevent acute rejection. In one model, anti-CD40L is 
administered after B6-to- BALB/c (H2d) heterotopic cardiac transplantation. Without 
manipulation, cardiac allografts are promptly rejected; however, if treated with anti-CD40L, 
acute rejection is ameliorated, and recipients develop chronic rejection. In this model, 
approximately 50% of cardiac allografts survive 100 days, but with severe evidence of 
histologic chronic allograft changes (Bedi et al., 2010). 
5.2 Aorta transplantation 
Abdominal aorta transplantation has been widely used in rodents as a model for TV (i.e. 
Murphy, Bicknell, & Nicholson, 2003)) and involves substitution of a part of the recipient’s 
distal aorta with a donor graft. One of the first aortic allograft models for chronic rejection in 
the rat was described by Mennader (Mennander et al., 1991) and Isik (Isik et al., 1992). They 
revealed histologic features that parallel those seen in the vessels of human transplanted 
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organs (Isik et al., 1992). Similar methods in mice have been described by Koulack et al. 
(Koulack et al., 1995) and have been further modified (i.e. (Ensminger et al., 2002)). The 
histologic features are an initial increase in mononuclear inflammatory cells with gradually 
increasing numbers of smooth muscle cells resulting in intimal thickening of the aorta and at 
later time points in deposition of extracellular matrix and collagen fibrils (Isik et al., 1992). 
Aortic allografts transplantation represents an alternative model for evaluation of the 
influence of novel transplant strategies on transplant arteriosclerosis. Vascular changes can 
be easily and more precisely quantified due to faciliated access to the aortic graft thus 
providing representative sections (Isik et al., 1992; Mennander et al., 1991). In contrast, 
quantification of TV in rat and mouse cardiac allografts is reportedly difficult and the 
interpretation of the data obtained controversial (Ensminger et al., 2000; Isik et al., 1992). 
The aortic transplantation is a useful model for the study of vascular repair. Due to the 
absence of the impact of supporting parenchyma it is questionable whether vascular 
changes in aortic allografts are representative for chronic vascular rejection in solid-organ 
transplants (Libby & Pober, 2001). Nevertheless, Ensminger et al. reported in a combined 
cardiac and aortic transplant model on equivalent outcome of TV in abdominal aortic 
allografts in the presence as well as in the absence of an additional organ transplant 
(Ensminger et al., 2000). Moreover, although heterotopic cardiac transplantation might be a 
more suitable model, the aortic transplantation model is helpful in understanding the 
endothelial milieu during chronic allograft injury. 
5.3 Other models of cardiac fibrosis 
Most other models of cardiac fibrosis involve mechanic or pharmacologic intervention aimed 
at increasing the cardiac workload. The mechanic approach involves partial constriction at 
various levels of the aortic arch. The pharmacologic approach involves the infusion of 
angiotensin or aldosterone. Angiotensin treatment leads to fibrosis development within 2 
weeks and increases with time (Sun & Weber, 2005), whereas the aldosterone model also 
requires reduction of functional kidney mass (unilateral nephrectomy) and subsequent high 
sodium diet, therefore requiring more than 4 weeks to develop fibrosis (Sun & Weber, 2005). 
5.4 Selected features of non-cardiac models of fibrosis 
A large number of fibrosis models in other organs have been described and are thought to 
have particular relevance to fibrosis in that specific organ. Inducing agents can be 
alloreactivity, chemical irritants, high-fat diet (relevant to liver fibrosis) or secretory 
obstruction (bile or urine). However, it is worth noting that a comparison between organs 
may provide a more efficient search for core pathways essential to convert an initial 
stimulus to the development of fibrosis (Mehal et al., 2011). Likewise, none of the models, 
currently considered relevant to understanding cardiac fibrosis development, are well 
suited for “high-throughput” analyses because they are technically demanding and require 
a relatively long time to develop the lesion. 
Unilateral ureteral obstruction (UUO) is an inducible animal model in rodents for human 
obstructive nephropathy leading to tubolointerstitial fibrosis. It has become a standard 
model of nonimmunological tubulointerstitial fibrosis in which the ureter of one kidney is 
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obstructed by ligation. Obstruction can be partial or total. With complete obstruction, 
fibrosis can generally be observed within 1-2 weeks, depending on the species and strain 
used in the experimental setting. A substantial advantage of the UUO model over complex 
transplantation models is technical simplicity and a relatively short time required to develop 
the lesions. Other assets are absence of exogenous toxin and the contralateral organ serving 
as control (Chevalier et al., 2009).  
6. Conclusion 
Transplant vasculopathy and interstitial fibrosis remain key clinical obstacles to achieve 
long-term survival of solid organ allografts. Although to date relatively little data has been 
generated to address the role of matricellular proteins directly in this context, there is 
considerable circumstantial evidence from surrounding fields to foresee that their functions 
may be central to allograft-associated fibrosis development. Several models of cardiac 
fibrosis are well-established but time consuming. This limitation may be seen in light of the 
recently proposed strategy to identify core pathways of fibrosis by simultaneously 
comparing the process in several different organs. 
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